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OBJECTIVES We investigated the acute and long-term hemodynamic and neurohumoral effects of the
vasopeptidase inhibitor omapatrilat in human heart failure.
BACKGROUND Angiotensin-converting enzyme (ACE) inhibition constitutes a major advance in the
treatment of chronic heart failure (CHF). Simultaneous inhibition of both neutral endopep-
tidase and ACE with omapatrilat may represent a new treatment strategy in CHF.
METHODS Three hundred and sixty-nine patients with symptomatic heart failure were randomized to
double-blind treatment with omapatrilat (first 190 patients: 2.5 mg, 5 mg or 10 mg; last 179
patients: 2.5 mg, 20 mg or 40 mg once daily) for 12 weeks.
RESULTS Acutely, the 10 mg, 20 mg and 40 mg doses of omapatrilat produced greater reductions in
pulmonary capillary wedge pressure (PCWP), systolic blood pressure (SBP) and systemic vascular
resistance compared with 2.5 mg. Higher doses were associated with greater increases in
vasodilator and natriuretic peptides, in addition to ACE inhibition. After 12 weeks, omapatrilat
20 mg and 40 mg showed greater falls from baseline in PCWP (40 mg: 0 h to 12 h average change
7.3  0.8 mm Hg) and SBP (40 mg: 11.7  1.7 mm Hg) than 2.5 mg (both p  0.01 vs.
2.5 mg). The incidence of adverse experiences and patient withdrawal were similar in all groups.
CONCLUSIONS In CHF, the acute hemodynamic benefit seen with higher doses of omapatrilat was associated
with increases in plasma vasodilator and natriuretic peptide levels in addition to ACE
inhibition. After 12 weeks, the hemodynamic benefit was maintained. Omapatrilat may be a
promising new agent in CHF. (J Am Coll Cardiol 2002;39:2034–41) © 2002 by the
American College of Cardiology Foundation
Angiotensin-converting enzyme (ACE) inhibition consti-
tutes a major advance in the treatment of chronic heart
failure (CHF), with symptomatic improvement and some
survival gains (1). However, despite the first line use of
ACE inhibitors and, more recently, beta-adrenergic block-
ing agents, the prognosis of CHF remains poor (1,2).
The natriuretic peptides are counter-regulatory to the
renin-angiotensin system, causing vasodilation, diuresis and
natriuresis (3–5). Augmentation of their levels with exog-
enously administered atrial natriuretic peptide (ANP) and
brain natriuretic peptide (BNP) has resulted in a reduction
in filling pressures, natriuresis and diuresis in acute studies
in CHF (4,5). However, their therapeutic usefulness is
limited by a short half-life, due to rapid degradation by
neutral endopeptidase (NEP) (6). Other NEP substrates
include bradykinin (7) and adrenomedullin (ADM) (8).
Omapatrilat is the first of a new class of drugs known as
vasopeptidase inhibitors, which simultaneously inhibit both
NEP and ACE, resulting in increased levels of natriuretic
peptides and bradykinin, with a reduction in angiotensin II
(9,10). In patients with heart failure, omapatrilat therapy for
24 weeks showed a similar increase in week 12 exercise
tolerance but conferred more benefit than lisinopril in the
composite of death, hospital admission or discontinuation
of study treatment for worsening heart failure (11).
The purpose of this multicenter study was to evaluate the
hemodynamic and neurohumoral effects, safety and tolera-
bility of increasing doses of omapatrilat after a single oral
dose and after 12 weeks of once-daily oral therapy in
patients with symptomatic heart failure.
METHODS
Study design. Patients with stable symptomatic heart fail-
ure (New York Heart Association functional class II to IV),
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left ventricular ejection fraction 40% and in sinus rhythm
were eligible for enrollment in this multicenter double-
blind, randomized study. The protocol was approved by
local ethical committees, and all patients gave written,
informed consent.
Studies in normal human volunteers have shown evidence
of significant ACE inhibition with 2.5 mg to 75 mg doses
of omapatrilat (12,13), while dose-related NEP inhibition,
as measured by changes in urinary ANP and urinary cyclic
3,5-guanosine monophosphate (cGMP), was shown from
the 7.5-mg to the 75-mg dose (12). In contrast, the 2.5-mg
omapatrilat dose, although showing selective ACE inhibi-
tion, did not change urinary ANP and cGMP. Since ethical
considerations excluded a placebo control, the 2.5-mg dose
was used as an active control.
The study was conducted in two sequential, separate
panels. In panel I, patients were randomized to omapatrilat
2.5 mg, 5 mg or 10 mg once daily. In panel II, patients were
randomized to omapatrilat 2.5 mg, 20 mg or 40 mg once
daily. An analysis of safety data from the completed panel I
was performed before panel II started. Patients who were in
panel I were not eligible for panel II.
After enrollment, there was a 2- to 14-day single-blind
placebo lead-in period, where patients were stabilized on
diuretics and concomitant cardiac medications, with doses
remaining stable for 2 days before right heart catheteriza-
tion. Angiotensin-converting enzyme inhibitors or angio-
tensin II receptor antagonists were withdrawn for at least
four days before randomization. Patients were admitted for
right heart catheterization, performed at least 12 h before
baseline measurements. After an overnight fast, a minimum
of two baseline recordings (30 min apart with 10%
variability) with mean pulmonary capillary wedge pressure
(PCWP) 15 mm Hg; cardiac index (CI) 3.0 l/min/m2
and SBP 90 mm Hg were required to enter the 24-h
hemodynamic assessment phase.
Patients who qualified were then randomized to double-
blind therapy. Repeat hemodynamic measurements were
made at 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 9 h, 12 h and 24 h after
the first dose of the study drug. All other cardiac medica-
tions were withheld over the 24-h period of hemodynamic
monitoring.
Subjects were continued for 12 weeks on double-blind
study drug. All other medications (except ACE inhibitors or
angiotensin II receptor antagonists) were restarted and
continued throughout the 12 weeks. Outpatient evaluations
were performed at weeks 1, 2, 4, 6 and 8. Up to four
supplemental doses of diuretics were permitted for worsen-
ing heart failure, with no supplemental doses permitted
within 72 h before hemodynamic measurements. Patients
were withdrawn from the study if an increase in the daily
maintenance dose of diuretic or other heart failure medica-
tion was required. The diuretic dose could be decreased to
correct serum creatinine 3.0 mg/dl (265 mol/l) or to
correct symptomatic hypotension.
After 12 weeks, patients underwent a second right heart
catheterization. On the morning of the next day, the study
medication was administered after two consecutive predose
recordings showed 10% variability in PCWP and CI;
repeat measurements were performed over a similar 24-h
period as on day 1. All other medications were withheld
during the 24-h period.
Methodology. Hemodynamic assessment was performed
the day after placement of a balloon-tipped thermodilution
catheter in the pulmonary artery. Pulmonary arterial pres-
sures and electrocardiogram were measured continuously,
cardiac output was measured by the thermodilution tech-
nique, and arterial blood pressures by brachial sphygmoma-
nometry. All measurements were performed in triplicate in
the semisupine position. Cardiac index and systemic vascu-
lar resistance (SVR) were calculated using standard formulas
(14). Physician and subject assessments of the change in
functional status were performed at three months or on
withdrawal from study using a global assessment scale:
improved (greatly, moderately or slightly), unchanged or
worsened. Subjects participating in the neurohormonal
substudy had venous blood drawn during both hemody-
namic monitoring periods (day 1 and week 12), predose and
at 3 h, 12 h and 24 h after dose.
Measurement of plasma ANP, BNP, cGMP, ADM,
aldosterone, endothelin-1 (ET-1), renin and ACE activity
was performed by radioimmunoassay, and norepinephrine
and epinephrine by higher performance liquid chromatog-
raphy (12,15–21). All samples were analyzed in duplicate.
Intraassay coefficients of variation were 9%.
Statistical analysis. The primary efficacy measure was the
change from baseline in PCWP determined at week 12. A
sample size of 45 subjects per group in panel I and 35
subjects per group in panel II was planned to allow detection
with power  0.80 of a 4.3 mm Hg (4.9 mm Hg in panel
II) mean difference in PCWP between the high and low
dose groups (standard deviation of difference assumed 
7.3 mm Hg).
A time-weighted average change from baseline (baseline
defined as the day 1 predose value) was calculated for each
hemodynamic parameter, averaged over the first 12 h after
the first dose (acute response) and over the first 12 h after
the last dose (week 12 response). The acute and week 12
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ADM  adrenomedullin
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
cGMP  cyclic 3,5-guanosine monophosphate
CHF  chronic heart failure
CI  cardiac index
ET-1  endothelin-1
NEP  neutral endopeptidase
PCWP  pulmonary capillary wedge pressure
SBP  systolic blood pressure
SVR  systemic vascular resistance
2035JACC Vol. 39, No. 12, 2002 McClean et al.
June 19, 2002:2034–41 Hemodynamic Effects of Omapatrilat in Heart Failure
time-weighted changes were each evaluated by analysis of
covariance, with resulting comparisons of each dose group
to its corresponding 2.5 mg control group made using
Fisher least significant difference test. Comparisons were
made within panels only, so as to reflect the manner in
which the randomization was performed. All tests were
two-sided with alpha  0.05. To maintain control of the
type I error at alpha, pairwise testing to the 2.5 mg control
dose was performed in a sequential manner, from the
highest dose on down, with the testing sequence stopping
upon identifying a dose with a nonsignificant (p  0.05)
result.
For neurohormones the change from baseline (baseline
defined as the day 1 predose value) was calculated for each
parameter at 3 h, 12 h and 24 h after the first dose of study
medication and at the same time points after the last dose of
study medication at week 12. A 95% confidence interval for
the mean change at each time point compared with the
2.5-mg control was calculated for each dose group.
New York Heart Association functional changes, as well
as assessments of change in heart failure status, were
compared among dose groups within each panel using the
Cochran-Mantel-Haenszel test. For describing safety, in-
cluding the incidence of adverse events, data from the two
2.5-mg dose groups were pooled.
RESULTS
Of the 565 patients who were enrolled, 369 met the
entrance criteria, with 190 randomized in panel I of the
study and 179 in panel II (Table 1). Nine patients did not
complete the first 24-h assessment, and 79 discontinued
before week 12. Hemodynamic data were available for the
first 24 h and after 12 weeks of therapy in 360 and 281
patients, respectively. Fifty-nine patients in panel I and 44
patients in panel II (divided evenly among dose groups)
completed the neurohormonal substudy.
Hemodynamic measurements. After the initial dose of
omapatrilat, the 0-h to 12-h average reduction in PCWP
from baseline was significantly greater in the 10 mg, 20 mg
and 40 mg groups (all p  0.01 vs. 2.5 mg) (Table 2). After
12 weeks of therapy, the 0-h to 12-h average reduction in
PCWP from baseline (baseline defined as the day 1 predose
value) was significantly greater with the 20 mg and 40 mg
doses (both p  0.01 vs. 2.5 mg) (Fig. 1a). Cardiac index
did not change with higher doses compared with 2.5 mg
acutely, or after chronic therapy.
Dose-related falls in systolic blood pressure (SBP) were
seen acutely. On day 1, the 0-h to 12-h average reduction in
SBP from baseline was significantly greater in the 10 mg,
20 mg and 40 mg groups (all p  0.01 vs. 2.5 mg). After
12 weeks, greater falls from baseline in SBP were seen with
Table 1. Baseline Demographics
Panel I Panel II
Omapatrilat Dose 2.5 mg 5 mg 10 mg 2.5 mg 20 mg 40 mg
Total No. 63 66 61 59 58 62
Age (yrs), mean (SD) 60.4 (11.5) 59.6 (12.8) 62.2 (12.7) 58.7 (11.1) 61.0 (10.5) 60.3 (11.2)
NYHA functional class (%)
II 22 (35) 17 (26) 28 (46) 26 (44) 29 (50) 23 (37)
III 37 (59) 46 (70) 29 (48) 32 (54) 27 (47) 34 (55)
IV 4 (6) 3 (5) 4 (7) 1 (2) 2 (3) 5 (8)
LVEF (%), mean (SD) 23.3 (8.5) 24.3 (7.7) 23.4 (7.7) 23.1 (6.6) 25.6 (7.9) 23.5 (8.5)
CHF duration (months), mean (SD) 43.8 (39.0) 38.6 (33.0) 42.1 (46.9) 43.9 (38.9) 45.9 (50.0) 47.6 (40.9)
Etiology of heart failure
Ischemic 35 (56%) 45 (68%) 36 (59%) 40 (68%) 33 (57%) 37 (60%)
Idiopathic 18 (29%) 15 (23%) 16 (26%) 14 (24%) 15 (26%) 18 (29%)
Hypertensive 7 (11%) 4 (6%) 7 (11%) 5 (8%) 8 (14%) 5 (8%)
Valvular 2 (3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Other 1 (2%) 2 (3%) 2 (3%) 0 (0%) 2 (3%) 4 (2%)
Baseline hemodynamic measurements,
mean (SE)
PCWP (mm Hg) 21.6 (0.7) 23.2 (0.9) 22.9 (1.0) 22.4 (0.8) 22.2 (0.9) 22.2 (0.7)
CI (l/min/m2) 2.29 (0.06) 2.22 (0.06) 2.18 (0.06) 2.27 (0.06) 2.39 (0.06) 2.30 (0.06)
SBP (mm Hg) 129.2 (2.5) 127.2 (2.2) 132.0 (2.7) 131.8 (2.6) 135.3 (2.9) 129.6 (2.7)
MSAP (mm Hg) 94.2 (1.4) 92.8 (1.3) 94.8 (1.6) 95.5 (1.8) 94.9 (1.8) 93.9 (1.8)
SVR (dynes.s/cm5) 1,645 (51) 1,607 (53) 1,715 (67) 1,602 (55) 1,577 (61) 1,612 (54)
Previous cardiovascular medications
Beta-blockers 9 (14%) 15 (23%) 8 (13%) 20 (34%) 20 (34%) 21 (34%)
Diuretics 58 (92%) 62 (94%) 54 (89%) 52 (88%) 54 (93%) 59 (95%)
ACE inhibitors 55 (87%) 60 (91%) 54 (89%) 51 (86%) 48 (83%) 50 (81%)
A II inhibitors 7 (11%) 6 (9%) 4 (7%) 6 (10%) 6 (10%) 7 (11%)
A II  angiotensin II; ACE  angiotensin-converting enzyme; CHF  congestive heart failure; CI  cardiac index; LVEF  left ventricular ejection fraction; MSAP  mean
systolic arterial pressure; NYHA  New York Heart Association; PCWP  pulmonary capillary wedge pressure; SBP  systolic blood pressure; SVR  systemic vascular
resistance.
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both the 20 mg (p  0.05) and 40 mg (p  0.01) doses
compared with 2.5 mg (Fig. 1b).
On day 1, SVR fell more with the 10 mg, 20 mg and
40 mg doses (all p  0.05 vs. 2.5 mg). At week 12, SVR
tended to fall in all groups; reductions from baseline in SVR
with higher doses of omapatrilat were not significantly
greater than in the 2.5-mg groups. Acutely, heart rate was
reduced more in the 40-mg group (p  0.05 vs. 2.5 mg),
with no difference after chronic dosing.
Neurohormones. On day 1, changes in neurohormones
occurred mainly at 3 h after dose (Table 3). By 12 h all
neurohormones had returned to baseline levels, except
plasma ACE activity and plasma renin. Plasma ACE
activity decreased from baseline in all dose groups, with a
greater reduction seen at all dose groups above 2.5 mg.
Plasma renin increased from baseline at 12 h and 24 h in all
dose groups except 2.5 mg. Greater increases in plasma
ANP were seen at 3 h with 10 mg (22  8 pmol/l), 20 mg
and 40 mg doses compared with the 2.5 mg control groups.
This was mirrored by dose-related increases in the plasma
second messenger cGMP. Brain natriuretic peptide also
increased at 3 h with 10 mg (7  2 pmol/l) and 40 mg
compared with 2.5 mg. The 40-mg dose also caused a
greater rise in plasma ADM at 3 h versus 2.5-mg control,
with no difference in aldosterone. Plasma ET-1 and nor-
epinephrine both showed an initial rise at 3 h with 40 mg
compared with 2.5 mg.
After 12 weeks of chronic therapy, the increase in plasma
renin from predose day 1 baseline levels was higher with
40 mg (2.2  0.5 nmol/l/h) compared with 2.5 mg (0.1 
Table 2. Average Changes From Baseline in Hemodynamic Variables
Panel I Panel II
2.5 mg 5 mg 10 mg 2.5 mg 20 mg 40 mg
PCWP (mm Hg)
0–12 h  day 1 3.2  0.5 3.8  0.5 5.9  0.5† 3.6  0.4 7.2  0.4† 7.5  0.4†
24 h day 1 2.4  0.7 1.6  0.7 3.6  0.7 2.6  0.7 3.6  0.7 3.4  0.7
Predose week 12 2.0  1.0 3.2  1.0 4.3  1.0 2.5  1.0 3.4  1.1 3.4  1.1
0–12 h  week 12 5.0  0.8 5.5  0.8 7.1  0.9 3.6  0.8 7.1  0.8† 7.3  0.8†
CI (l/min/m2)
0–12 h  day 1 0.07  0.03 0.11  0.03 0.13  0.03 0.10  0.04 0.14  0.04 0.07  0.04
24 h day 1 0.09  0.05 0.16  0.05 0.17  0.05 0.09  0.05 0.21  0.05 0.11  0.05
Predose week 12 0.08  0.07 0.10  0.07 0.11  0.08 0.14  0.06 0.20  0.07 0.17  0.06
0–12 h  week 12 0.00  0.07 0.12  0.07 0.15  0.07 0.12  0.06 0.21  0.06 0.15  0.06
SBP (mm Hg)
0–12 h  day 1 4.9  1.1 7.1  1.1 13.3  1.2† 4.3  1.2 13.5  1.2† 14.9  1.2†
24 h day 1 4.6  2.0 0.4  2.0 7.7  2.1 3.8  1.8 3.8  1.6 5.6  1.5
Predose week 12 4.5  1.6 1.5  1.6 6.2  1.7 2.0  2.1 4.5  2.2 5.6  2.1
0–12 h  week 12 8.6  1.6 5.8  1.7 11.4  1.7 4.6  1.7 10.7  1.7* 11.7  1.7†
MSAP (mm Hg)
0–12 h  day 1 3.9  0.8 5.0  0.8 9.5  0.8† 3.4  0.8 10.3  0.8† 11.5  0.8†
24 h day 1 2.2  0.9 0.1  0.8 4.5  0.9 2.0  1.1 3.3  1.2 4.2  1.1
Predose week 12 4.4  1.3 0.3  1.3 2.9  1.3 1.7  1.4 4.0  1.5 5.1  1.4
0–12 h  week 12 6.9  1.2 3.6  1.2 7.1  1.2 4.1  1.2 8.5  1.2* 9.9  1.2†
SVR (dynes.s/cm5)
0–12 h  day 1 99  27 146  27 234  28* 94  30 209  31* 190  30*
24 h day 1 76  39 81  37 182  39 71  40 181  40 112  39
Predose week 12 8  57 30  57 119  59 118  50 116  52 181  30
0–12 h  week 12 77  46 99  47 199  49 146  43 175  42 199  42
HR (beats/min)
0–12 h  day 1 1.5  0.8 0.4  0.8 1.2  0.8 0.7  0.7 0.3  0.7 1.7  0.6*
24 h day 1 4.1  1.0 3.2  0.9 0.5  1.0 1.4  1.0 4.1  1.0 2.6  1.0
Predose week 12 1.6  1.3 2.4  1.3 2.2  1.3 2.3  1.3 2.4  1.4 5.6  1.3
0–12 h  week 12 0.2  1.2 0.8  1.3 0.7  1.3 1.4  1.2 1.9  1.2 3.3  1.2
PADP (mm Hg)
0–12 h  day 1 1.9  0.4 2.9  0.4 5.4  0.4* 2.4  0.4 5.5  0.4† 5.8  0.4†
24 h day 1 0.9  0.7 1.2  0.7 3.5  0.7 1.9  0.7 1.2  0.8 2.4  0.7
Predose week 12 1.3  0.9 1.9  0.9 3.8  0.9 1.9  1.0 2.5  1.0 2.6  1.0
0–12 h  week 12 3.3  0.8 3.7  0.8 5.7  0.8 2.9  0.8 5.9  0.8* 5.0  0.8
MRAP (mm Hg)
0–12 h  day 1 0.9  0.3 1.6  0.3 1.7  0.3 0.8  0.2 2.4  0.2† 2.3  0.2†
24 h day 1 0.3  0.5 1.1  0.5 1.3  0.6 2.1  0.5 1.2  0.6 1.3  0.6
Predose week 12 1.4  0.5 0.9  0.8 1.2  0.6 1.2  0.6 1.5  0.7 0.4  0.6
0–12 h  week 12 2.0  0.5 1.5  0.5 1.9  0.6 1.1  0.5 2.8  0.5* 1.8  0.5
Average changes from predose day one baseline (mean  SEM). 0–12 h day 1  0–12 h average change after first omapatrilat dose; 24 h day 1  change at 24 h after first
dose; predose week 12  change from predose day 1; 0–12 h week 12  0–12 h average change after final omapatrilat dose. *p  0.05; †p  0.01, vs. 2.5 mg dose.
HR  heart rate; MRAP  mean right atrial pressure; PADP  pulmonary artery diastolic pressure. Other abbreviations as in Table 1.
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0.6 nmol/l/h, mean difference 2.3 nmol/l/h; 95% confidence
interval: 0.6 to 3.8) and remained elevated at all time points
after final dose. Plasma ACE activity decreased 3 h after
final dose in the 10 mg, 20 mg and 40 mg (21 
1.0 nmol/ml/min) groups compared with 2.5 mg (11 
1 nmol/ml/min) (mean difference 9.8 nmol/ml/min; 95%
confidence interval: 14 to 6). Atrial natriuretic peptide
tended to increase at 3 h with 40 mg (56  21 pmol/l)
compared with 2.5 mg (1 	 23 pmol/l) (mean difference
55 pmol/l; 95% confidence interval:9 to 118). There were
no changes in any other neurohormone (including ET-1
and norepinephrine) at 12 weeks.
Safety and tolerability. Nine patients were withdrawn
after the first dose. Four withdrew due to first-dose hypo-
tension, but there were no serious consequences (Table 4).
Incidence of first dose hypotension was 0% on 2.5 mg, 3%
on 5 mg, 9.8% on 10 mg, 5.2% on 20 mg and 8.1% on 40
mg. Angioedema was reported in one subject, after the first
dose of omapatrilat 40 mg.
Over the 12 weeks, there were eight deaths spread evenly
among the groups. The percentage of patients who discon-
tinued was similar in all groups (Table 4). Overall adverse
experiences occurred with a similar frequency in all groups.
The incidence of symptomatic hypotension at any time over
12 weeks was 4.9% on 2.5 mg, 7.6% on 5 mg, 16.4% on
10 mg, 20.7% on 20 mg and 12.9% on 40 mg. The overall
incidence of cough was 11.4%, with 9.8% on 2.5 mg, 12.1%
on 5 mg, 11.5% on 10 mg, 6.9% on 20 mg and 17.7% on
40 mg. Exacerbation of heart failure was seen in 30.3% on
2.5 mg; 27.3% on 5 mg; 26.2% on 10 mg; 25.9% on 20 mg
and 19.4% on 40 mg (p  NS). New York Heart Associ-
ation functional class improved in all groups, with no
difference between groups for the physician and subject
global assessments of change in heart failure status.
DISCUSSION
Vasodilation and fluid volume are regulated by a number of
interrelated neurohumoral systems, including the renin-
angiotensin-aldosterone system and the natriuretic peptides.
This study evaluated the hemodynamic effects of the va-
sopeptidase inhibitor omapatrilat and its effect on these
systems.
Acute effects. The 2.5-mg control dose caused a fall in
plasma ACE activity, without changes in plasma natriuretic
peptide levels, consistent with the action of an ACE
inhibitor. The degree of ACE inhibition intensified as the
dose was increased, resulting in beneficial hemodynamic
Figure 1. Change from pretreatment day 1 baseline levels in pulmonary capillary wedge pressure (PCWP) (a) and systolic blood pressure (SBP) (b) after
the final dose of omapatrilat at 12 weeks. Panel I: open diamond  2.5 mg; star  5 mg; open triangle  10 mg. Panel II:   2.5 mg; open square 
20 mg; open circle  40 mg. Shaded symbols indicate a significant difference (p  0.05) in the 0-h to 12-h average change from predose day 1 for
omapatrilat dose compared with the respective 2.5 mg group.
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effects. Despite this, increasing the dose above 10 mg did
not result in further dose-related peak hemodynamic effects,
but higher doses of omapatrilat influenced several other
vasoactive hormone systems. Increases in ANP and BNP
acutely with plasma second messenger cGMP suggest the
presence of NEP inhibition, in addition to ACE inhibition.
Neurohormonal changes at 3 h coincided with reductions in
left ventricular filling pressures and SVR. By 12 h after dose,
plasma neurohormones had returned towards baseline, de-
spite the persisting falls in PCWP, SVR and mean atrial
pressure. This may reflect reduced secretion in response to
improved hemodynamics or decreased NEP inhibition.
Increases in plasma ET-1 at 3 h acutely suggests inhibition
of the degradation of ET-1 due to NEP inhibition (22).
Baroreceptor-mediated sympathetic discharge, in response
to the significant fall in blood pressure, may have contrib-
uted to the acute increase in norepinephrine at 3 h with the
40-mg dose, in contrast to no change with epinephrine.
Chronic treatment. After chronic therapy, continued
ACE inhibition was evident with increases in plasma renin
and reductions in plasma ACE activity in all groups. With
the highest dose, ANP tended to increase 3 h after dose at
week 12. Importantly, there were no increases in potentially
deleterious hormones such as endothelin and norepineph-
rine with chronic dosing. After 12 weeks, the hemodynamic
improvements were sustained up to at least 12 h, suggesting
lack of tolerance with chronic therapy. Greater falls were
seen in higher dose groups for PCWP, SBP and mean
systolic arterial pressure. The lack of further dose-related
peak hemodynamic effects from 10 mg to 40 mg may be due
to a combination of factors. Possible tissue NEP inhibition,
in addition to ACE inhibition, may have occurred with the
lower doses. Although the 0 h to 12 h average reduction in
SVR in the 40-mg group at week 12 was similar to day 1,
increased chronic effects of the 2.5-mg ACE inhibitor
control may have negated a significant dose-related change.
Fewer patients in panel I received chronic beta-blockade,
which may have enhanced the 10-mg effect. Although no
difference in CI occurred between high and low dose
groups, CI appeared to increase in most groups acutely and
with chronic therapy.
Omapatrilat acutely increased plasma levels of ADM,
another potent renal vasodilating and natriuretic peptide
(8). Higher doses of omapatrilat have been shown to have a
natriuretic effect in CHF (14), which may be, in part, due to
local renal effects of both natriuretic peptides and ADM.
Safety and tolerability. The first dose was safely tolerated
by most patients. First dose hypotension was generally
minor, transient and well tolerated but resulted in treatment
withdrawal of four patients. It is likely that hypotension
would be less common in clinical practice where dose
titration would be used. Only three additional withdrawals
for hypotension occurred over the 12 weeks. The incidence
of withdrawal for any reason with chronic therapy was
similar in all groups. The strict study criterion of no increase
in maintenance diuretics and the requirement for repeat
invasive catheterization both may have affected the with-
drawal rate. The incidence of cough appeared to be similar
to previously published ACE inhibitor studies (23). Angio-
edema occurred in one patient of 369 patients randomized.
Study limitations. The use of an active control limb, the
finding that most patients were receiving an ACE inhibitor
before enrollment and the short washout period are all likely
to have resulted in underestimation of the magnitude of
drug effect, especially as some variables such as CI and SVR
may worsen over time with placebo (24). However, it is not
ethically permissible to include a chronic placebo arm (25).
The small numbers in the neurohormone substudy may not
be representative of the group as a whole. In addition, the
variable number of withdrawals among treatment groups
over 12 weeks may have affected the validity of the week 12
results. The duration of plasma NEP inhibition appeared to
be shorter than that of plasma ACE inhibition, suggesting
more frequent dosing; however, tissue NEP inhibition was
not measured.
Table 3. Changes From Baseline in Plasma Neurohormones at
3 h on Day 1 (Panel II)
Dose
(mg)
Changes at 3 h
From Predose
Baseline
Difference
(95% CI) vs.
Omapatrilat
2.5 mg
ANP (pmol/l) 2.5 6  11
20 48  11 43 (11, 74)
40 53  10 47 (17, 77)
BNP (pmol/l) 2.5 0  2
20 4  2 4 (1, 9)
40 8  2 9 (4, 13)
cGMP (nmol/l) 2.5 3  2
20 8  2 5 (1, 10)
40 12  2 9 (5, 14)
ADM (pmol/l) 2.5 1  1
20 4  1 3 (0, 7)
40 6  1 5 (2, 9)
ACE activity
(nmol/ml/min)
2.5 10  1
20 20  1 10 (13 to 7)
40 22  1 12 (15 to 8)
RENIN (nmol/l/h) 2.5 0  1
20 2  2 2 (1 to 5)
40 3  1 3 (0 to 6)
ALDO (pmol/l) 2.5 79  21
20 104  20 25 (-83, 32)
40 42  19 36 (20, 92)
ET-1 (pmol/l) 2.5 0.0  0.1
20 0.4  0.1 0.3 (0.0 to 0.7)
40 0.8  0.1 0.7 (0.4 to 1.1)
NOREPI (pmol/l) 2.5 80  170
20 30  166 111 (360 to 590)
40 440  160 523 (60 to 980)
EPI (pmol/l) 2.5 43  27
20 22  26 21 (55 to 97)
40 27  25 70 (4 to 140)
Changes in plasma neurohormones for panel II at 3 h on day 1 (Mean  SEM).
ACE  angiotensin-converting enzyme; ADM  adrenomedullin; ALDO 
aldosterone; ANP  atrial natriuretic peptide; BNP  brain natriuretic peptide;
cGMP  cyclic guanosine monophosphate; CI  confidence interval; EPI 
epinephrine; ET-1  endothelin-1; NOREPI  norepinephrine.
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CONCLUSIONS
In patients with mild-to-moderate CHF, the vasopeptidase
inhibitor omapatrilat results in acute beneficial hemody-
namic changes that are maintained after chronic dosing with
no attenuation of effect. Acute increases in plasma natri-
uretic peptide levels with higher doses, despite a reduction
in left ventricular filling pressures, are indicative of NEP
inhibition. No adverse neurohumoral effects were seen with
chronic therapy. Results from a larger trial, adequately
powered for morbidity and mortality end points (Omapat-
rilat Versus Enalapril Randomized Trial of Utility in Re-
ducing Events [OVERTURE]), are now awaited to assess
the long-term clinical efficacy of omapatrilat in CHF.
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